RA
IDIX

Royce & Associates’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Royce & Associates’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-534,316
Closed -$3.22M – 1490
2014
Q1 		$3.22M Sell
534,316
-131,664
-20% -$918K 0.01% 969
2013
Q4 		$3.98M Sell
665,980
-70,020
-10% -$324K 0.01% 933
2013
Q3 		$3.83M Hold
736,000
– – 0.01% 918
2013
Q2 		$2.66M Buy
+736,000
New +$3.01M 0.01% 1004

Other funds holding IDIX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royce & Associates's IDIX Position: Q2 2014 in Review

Royce & Associates sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q2 2014, closing a stake of 534,316 shares — an estimated $3.22M sold.

Royce & Associates first reported a position in IDIX in Q2 2013 and held it in 4 quarters. The position peaked at $3.98M in Q4 2013. 131 funds tracked by Wall St. Rank hold IDIX as of Q2 2014.

  • Royce & Associates reported no remaining IDENIX PHARMACEUTICALS INC position as of Q2 2014 after selling out during the quarter.
  • Royce & Associates sold 534,316 IDENIX PHARMACEUTICALS INC shares in Q2 2014, an estimated $3.22M.
  • Royce & Associates first reported a position in IDENIX PHARMACEUTICALS INC in Q2 2013 and held it in 4 quarters.
  • Royce & Associates's IDENIX PHARMACEUTICALS INC position peaked at $3.98M in Q4 2013.
  • 131 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q2 2014.

Based on Royce & Associates's 13F filing for Q2 2014, filed 11 Aug 2014.